Don't Ignore The Insider Selling In Xeris Biopharma Holdings

Anyone interested in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) should probably be aware that the Chief Legal Officer & Corporate Secretary, Beth Hecht, recently divested US$217k worth of shares in the company, at an average price of US$5.43 each. On the bright side, that sale was only 6.8% of their holding, so we doubt it's very meaningful, on its own.

The Last 12 Months Of Insider Transactions At Xeris Biopharma Holdings

Notably, that recent sale by Beth Hecht is the biggest insider sale of Xeris Biopharma Holdings shares that we've seen in the last year. So it's clear an insider wanted to take some cash off the table, even below the current price of US$5.81. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 6.8% of Beth Hecht's holding.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

See our latest analysis for Xeris Biopharma Holdings

I will like Xeris Biopharma Holdings better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Xeris Biopharma Holdings insiders own 4.8% of the company, worth about US$43m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The Xeris Biopharma Holdings Insider Transactions Indicate?

An insider sold stock recently, but they haven't been buying. And our longer term analysis of insider transactions didn't bring confidence, either. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Xeris Biopharma Holdings. At Simply Wall St, we've found that Xeris Biopharma Holdings has 2 warning signs (1 is a bit unpleasant!) that deserve your attention before going any further with your analysis.

Of course Xeris Biopharma Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.